Sinaptica featured on Mass Device
Sinaptica’s neurostim treatment for Alzheimer’s wins FDA Breakthrough nod Sinaptica Therapeutics announced today that it received FDA breakthrough device designation for its investigational...
View ArticleFDA breakthrough device designation stimulates increased interest
Sinaptica Therapeutics Inc. received a U.S. FDA breakthrough device designation for its electromagnetic therapy for Alzheimer’s disease. Sinaptistim-AD combines neurostimulation, brain wave...
View ArticleClik here to view.
Positive Phase II Alzheimer’s trial results Published
Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate...
View ArticleNoninvasive Brain Stimulation Shows Potential
Noninvasive Brain Stimulation Shows Potential to Slow Cognitive and Functional Decline in Mild-to-Moderate Alzheimer Disease Patients treated with PC-rTMS showed almost no decline in the CDR-SB score,...
View ArticleRepetitive TMS to the Precuneus Stabilizes Cognitive Status
This scientific commentary refers to ‘Precuneus magnetic stimulation for Alzheimer’s disease: a randomized, sham-controlled trial’ by Koch et al. (https://doi.org/10.1093/brain/awac285)....
View ArticleTMS-EEG perturbation biomarkers for Alzheimer’s disease patients classification
The combination of TMS and EEG has the potential to capture relevant features of Alzheimer’s disease (AD) pathophysiology. We used a machine learning framework to explore time-domain features...
View ArticleClik here to view.
Sinaptica Appoints Ken Mariash CEO
Company accelerates after unprecedented positive Phase 2 data in Alzheimer’s, showing >80% disease slowing on cognitive & functional endpoints CAMBRIDGE, Mass.-– Sinaptica Therapeutics, Inc., a...
View ArticleIt’s not just about plaques: rTMS also reduces cognitive and functional...
The growing number of drugs gaining U.S. FDA approval for Alzheimer’s disease has kept their ability to reduce amyloid beta and tau proteins in the news, but the degenerative disease is not simply a...
View ArticleClik here to view.
Sinaptica Therapeutics: MedTech Upstart Takes on Alzheimer’s with Radical New...
.elementor-widget-image-box .elementor-image-box-content{width:100%}@media (min-width:768px){.elementor-widget-image-box.elementor-position-left...
View ArticleAlzheimer’s Disease: Can Machine Learning Fix a Broken Brain Network?
Sinaptica began its commercial journey only recently, although its deep scientific underpinnings have already gotten it through a positive Phase II trial, which dramatically showed the benefit of a...
View ArticleShaping the Future of Alzheimer’s Care: Interview with Sinaptica CEO Ken Mariash
Researchers have been looking for a cure for Alzheimer’s disease for decades, with little success. Traditionally, the arsenal we’ve been using is largely reliant upon drugs. But could a device, not a...
View ArticleClik here to view.
Sinaptica Completes Scientific Advisory Board with Final Expert Appointment...
Giovanni Frisoni, MD joins SAB comprised of prominent global Alzheimer’s, neuromodulation and neuroscience experts including Jeffrey Cummings MD, ScD(HC); Ana Pereira MD; Simone Rossi MD, PhD; Casey...
View ArticleClik here to view.
Sinaptica Therapeutics Selected for StartUp Health’s Alzheimer’s Moonshot
Moonshot supported by Gates Ventures and Alzheimer’s Drug Discovery Foundation (ADDF)to accelerate innovation around Alzheimer’s Sinaptica is one of 14 companies initially selected that are advancing...
View ArticleClik here to view.
Insider Information: Nexstim Plc Announces Planned Alzheimer’s Collaboration...
Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) announces that it has successfully negotiated and signed a Letter of Intent (LOI) to exclusively collaborate with Sinaptica Therapeutics, Inc....
View ArticleClik here to view.
Alzheimer’s: Approaching a Cure
This Phase 2 trial showed 80 percent+ slowing of Alzheimer’s progression on gold standard cognitive and functional endpoints using non-invasive neuromodulation, leading to Sinaptica’s founding. I’ve...
View ArticleClik here to view.
Precision Neuromodulation Decreased Brain Atrophy and Increased Connectivity...
Study by Sinaptica scientific co-founders published in Alzheimer’s Research & Therapy Imaging analysis revealed personalized rTMS-EEG preserved structural integrity, enhanced functional...
View ArticleClik here to view.
Sinaptica’s Breakthrough Device Could Slow Brain Atrophy In Alzheimer’s...
Firm’s Is One Of Several FDA-Designated Breakthroughs Aiming To Outshine Drug Treatmentsby Ryan NelsonExecutive Summary In a pilot study building on previously published Phase 2 trial results,...
View ArticleClik here to view.
Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares...
VIEW FULL ARTICLE HERE Sinaptica On Precision Neuromodulation To Combat Alzheimer’s: ‘No Drug Dares Go After Moderate Patients’by Ryan Nelson CEO Ken Mariash and scientific co-founder Giacomo Koch...
View ArticleStartUp Health – Sinaptica Therapeutics: Bridging Neuroscience Gaps to Slow...
The post StartUp Health – Sinaptica Therapeutics: Bridging Neuroscience Gaps to Slow the Progression of Alzheimer’s Disease first appeared on Sinaptica Therapeutics™.
View ArticleClik here to view.
Sinaptica Therapeutics to Present Results of 52-week Phase 2 Study of...
Cambridge, MA – October 31, 2024 – Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and...
View Article